05:52 AM EDT, 07/29/2026 (MT Newswires) -- Hemogenyx Pharmaceuticals (HEMO.L) signed a letter of intent with Lithuania-based National Cancer Centre at Vilnius University Hospital Santaros Klinikos for a scientific and clinical collaboration to advance CAR-T therapy for blood cancers. The biopharmaceutical company said Wednesday that patient treatment will proceed under Lithuania's hospital exemption framework and other applicable pathways, in line with both Lithuanian law and the European Union rules governing advanced therapy medicinal products. Hemogenyx will retain full ownership of all intellectual property, related data, and regulatory rights connected to the therapy and its FLT3 CAR-T technology.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.